Search Results
Lead Bookrunner and Structuring Agent on Sound Point Meridian Capital, Inc.'s Initial Public Offering
Oppenheimer & Co. Inc. acted as Lead Bookrunner and Structuring Agent on Sound Point Meridian Capital, Inc’s Initial Public Offering
Joint Bookrunning Manager on Soleno Therapeutics
Oppenheimer &. Co. Inc. acted as Joint Bookrunning Manager on Soleno Therapeutics’ $158,700,000 confidentially marketed public offering of common stock
Joint Bookrunner to Murano Global Investments PLC Senior Secured Notes Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner to Murano Global Investments PLC on its $300 million 144A/Reg S Green Senior Secured Notes Offering
Joint Bookrunner & Sole Ratings Advisor to Trans-Oil Group on its New US$550m Senior Secured Eurobond
Oppenheimer’s European Capital Markets Group is pleased to announce it acted as Joint Global Coordinator and Joint Bookrunner & Sole Ratings Advisor to Trans-Oil Group on its new US$550m 11.125% 5NC2 high yield bond offering
Joint Bookrunner on Voyager Therapeutics Confidentially Marketed Public Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Voyager Therapeutics’ $100MM Confidentially Marketed Public Offering
Joint Bookrunner on Trevi Therapeutics' Underwritten Registered Direct Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Trevi Therapeutics' $50.0MM Underwritten Registered Direct Offering
Joint Bookrunner on the Upsized Senior Convertible Notes Offering for OSI Systems, Inc.
Oppenheimer & Co. Inc. acted as Joint Bookrunner on the Upsized $350,000,000 2.25% Senior Convertible Notes Offering for OSI Systems, Inc. (NASDAQ: OSIS)
Joint Bookrunner on Tarsus Pharmaceuticals
Oppenheimer &. Co. Inc. acted as Joint Bookrunner on Tarsus Pharmaceuticals’ $115MM Follow-On Offering
Joint Bookrunner on Perspective Therapeutics Registered Direct Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Perspective Therapeutics’ $80MM Registered Direct Offering
Joint Bookrunner on Capricor Therapeutics' Public Offering of Common Stock
Oppenheimer &. Co. Inc. acted as Joint Bookrunner on Capricor Therapeutics’ $86.3MM Confidentially Marketed Public Offering of Common Stock